{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:22:19Z","timestamp":1780518139955,"version":"3.54.1"},"reference-count":50,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81403003"],"award-info":[{"award-number":["81403003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702995"],"award-info":[{"award-number":["81702995"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1608283"],"award-info":[{"award-number":["U1608283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018617","name":"LiaoNing Revitalization Talents Program","doi-asserted-by":"publisher","award":["XLYC1907103"],"award-info":[{"award-number":["XLYC1907103"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Cytochrome P450 1B1(CYP1B1) is an extrahepatic P450 isoenzyme that can participate in\nprocesses of undermining the effectiveness and safety of anti-cancer therapy. Ginsenosides are the main active ingredients\nin ginseng, which possesses rich pharmacological activities, including anti-cancer activity and organ protection.\nHowever, the effect of ginsenosides on the activity of CYP1B1 remains unclear.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The present study aimed to investigate the inhibitory effect of ginsenosides on CYP1B1 and reveal the\nstructure-inhibitory activity relationship.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Firstly, recombinant CYP1B1 and EROD reactions were used to evaluate the inhibitory effect of ginsenosides.\nSecondly, molecular docking was used to simulate the interactions between ginsenosides and CYP1B1. Finally,\nthe structure-inhibitory activity relationship was analyzed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The ginsenosides, Rb2, Rd, and Rg3, significantly inhibited CYP1B1; the ginsenoside Rd showed the\nstrongest inhibition effect, with a Ki value of 47.37 \u03bcM in non-competitive mode. Notably, ginsenoside Rd formed\nhydrogen bonds with two key amino acid residues of CYP1B1, and one bond was between the glycosyl in position\n20 and ALA330, which also made ginsenoside Rd close to the heme iron of CYP1B1. In contrast, ginsenosides, Rb2\nand Rg3, which showed weaker inhibition, interacted with only one CYP1B1 residue by the hydrogen bond, which\nwas far away from the heme iron. Finally, the structure-inhibitory activity relationship analysis demonstrated that the\nnumber of glycosyls in position 20 and the type of sapogenins in the ginsenoside structure are the key factors determining\ninhibitory activity. Meanwhile, ALA330 was a vital amino acid in the potent inhibition of CYP1B1 by ginsenosides.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>A structure-dependent inhibitory effect on CYP1B1 was revealed for ginsenosides, among which ginsenoside\nRd showed the strongest inhibition due to its mono-glycosyl in position 20 of the ginsenoside parent structure.\nThese findings would provide evidence for the synthesis of novel CYP1B1 inhibitors to augment the anti-cancer\ntherapeutic effect.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200223666220601102629","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T09:38:52Z","timestamp":1654162732000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unraveling the Structure-Dependent Inhibitory Effects of Ginsenoside Series Compounds\non Human Cytochrome P450 1B1"],"prefix":"10.2174","volume":"23","author":[{"given":"Tingting","family":"Zhao","sequence":"first","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-8220","authenticated-orcid":true,"given":"Xiaodong","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dalian Municipal Women and\nChildren\u2019s Medical Center, Dalian, Liaoning, 116037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5152-1488","authenticated-orcid":true,"given":"Jie","family":"Du","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalong","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key Laboratory for Pharmacokinetics and Transport,\nLiaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key Laboratory for Pharmacokinetics and Transport,\nLiaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key Laboratory for Pharmacokinetics and Transport,\nLiaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key Laboratory for Pharmacokinetics and Transport,\nLiaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5046-9996","authenticated-orcid":true,"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key Laboratory for Pharmacokinetics and Transport,\nLiaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4065\/76.7.688","volume":"76","author":"Harnack L.J.","year":"2001","unstructured":"Harnack L.J.; Rydell S.A.; Stang J.; Prevalence of use of herbal products by adults in the Minneapolis\/St Paul, Minn, metropolitan area. Mayo Clin Proc 2001,76(7),688-694","journal-title":"Mayo Clin Proc"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1124\/dmd.30.4.378","volume":"30","author":"Chang T.K.","year":"2002","unstructured":"Chang T.K.; Chen J.; Benetton S.A.; In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos 2002,30(4),378-384","journal-title":"Drug Metab Dispos"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jgr.2018.02.004","volume":"42","author":"Yu J.S.","year":"2018","unstructured":"Yu J.S.; Roh H.S.; Baek K.H.; Lee S.; Kim S.; So H.M.; Moon E.; Pang C.; Jang T.S.; Kim K.H.; Bioactivity-guided isolation of ginsenosides from Korean Red Ginseng with cytotoxic activity against human lung adenocarcinoma cells. J Ginseng Res 2018,42(4),562-570","journal-title":"J Ginseng Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"112235","DOI":"10.1016\/j.ejmech.2020.112235","volume":"193","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; He X.; Li C.; Ma Y.; Xue W.; Hu B.; Wang J.; Zhang T.; Zhang F.; Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. Eur J Med Chem 2020,193,112235","journal-title":"Eur J Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/S0024-3205(00)00720-7","volume":"67","author":"Liu W.K.","year":"2000","unstructured":"Liu W.K.; Xu S.X.; Che C.T.; Anti-proliferative effect of ginseng saponins on human prostate cancer cell line. Life Sci 2000,67(11),1297-1306","journal-title":"Life Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/iub.1984","volume":"71","author":"Phi L.T.H.","year":"2019","unstructured":"Phi L.T.H.; Sari I.N.; Wijaya Y.T.; Kim K.S.; Park K.; Cho A.E.; Kwon H.Y.; Ginsenoside Rd inhibits the metastasis of colorectal cancer via epidermal growth factor receptor signaling axis. IUBMB Life 2019,71(5),601-610","journal-title":"IUBMB Life"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4062\/biomolther.2016.066","volume":"25","author":"Zhang Y.","year":"2017","unstructured":"Zhang Y.; Wang Y.; Ma Z.; Liang Q.; Tang X.; Tan H.; Xiao C.; Gao Y.; Ginsenoside Rb1 inhibits doxorubicin-triggered H9C2 cell apoptosis via Aryl Hydrocarbon receptor. Biomol Ther (Seoul) 2017,25(2),202-212","journal-title":"Biomol Ther (Seoul)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/ptr.6636","volume":"34","author":"Hou J.","year":"2020","unstructured":"Hou J.; Yun Y.; Xue J.; Jeon B.; Kim S.; Doxorubicin-induced normal breast epithelial cellular aging and its related breast cancer growth through mitochondrial autophagy and oxidative stress mitigated by ginsenoside Rh2. Phytother Res 2020,34(7),1659-1669","journal-title":"Phytother Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.phymed.2018.10.025","volume":"56","author":"Dai G.","year":"2019","unstructured":"Dai G.; Sun B.; Gong T.; Pan Z.; Meng Q.; Ju W.; Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-\u03b2\/Smad signaling. Phytomedicine 2019,56,126-135","journal-title":"Phytomedicine"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"33709","DOI":"10.1038\/srep33709","volume":"6","author":"Wang P.","year":"2016","unstructured":"Wang P.; Du X.; Xiong M.; Cui J.; Yang Q.; Wang W.; Chen Y.; Zhang T.; Ginsenoside Rd attenuates breast cancer metastasis implicating derepressing microRNA-18a-regulated Smad2 expression. Sci Rep 2016,6(1),33709","journal-title":"Sci Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/or.2017.5652","volume":"38","author":"Zhang E.","year":"2017","unstructured":"Zhang E.; Shi H.; Yang L.; Wu X.; Wang Z.; Ginsenoside Rd regulates the Akt\/mTOR\/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth. Oncol Rep 2017,38(1),359-367","journal-title":"Oncol Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/CAD.0000000000000781","volume":"30","author":"Chian S.","year":"2019","unstructured":"Chian S.; Zhao Y.; Xu M.; Yu X.; Ke X.; Gao R.; Yin L.; Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway. Anticancer Drugs 2019,30(8),838-845","journal-title":"Anticancer Drugs"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"E246","DOI":"10.3390\/nu12010246","volume":"12","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Fan D.; The preparation of ginsenoside Rg5, its antitumor activity against breast cancer cells and its targeting of PI3K. Nutrients 2020,12(1),E246","journal-title":"Nutrients"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3892\/or.2020.7728","volume":"44","author":"Hong S.","year":"2020","unstructured":"Hong S.; Cai W.; Huang Z.; Wang Y.; Mi X.; Huang Y.; Lin Z.; Chen X.; Ginsenoside Rg3 enhances the anticancer effect of 5 FU in colon cancer cells via the PI3K\/AKT pathway. Oncol Rep 2020,44(4),1333-1342","journal-title":"Oncol Rep"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.talanta.2011.10.051","volume":"88","author":"Zhou B.","year":"2012","unstructured":"Zhou B.; Xiao X.; Xu L.; Zhu L.; Tan L.; Tang H.; Zhang Y.; Xie Q.; Yao S.; A dynamic study on reversal of multidrug resistance by ginsenoside Rh in adriamycin-resistant human breast cancer MCF-7 cells. Talanta 2012,88,345-351","journal-title":"Talanta"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.phymed.2015.06.010","volume":"22","author":"Wang X.","year":"2015","unstructured":"Wang X.; Chen L.; Wang T.; Jiang X.; Zhang H.; Li P.; Lv B.; Gao X.; Ginsenoside Rg3 antagonizes adriamycin-induced cardiotoxicity by improving endothelial dysfunction from oxidative stress via upregulating the Nrf2-ARE pathway through the activation of AKT. Phytomedicine 2015,22(10),875-884","journal-title":"Phytomedicine"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"E3658","DOI":"10.3390\/ijms19113658","volume":"19","author":"Xu Z.M.","year":"2018","unstructured":"Xu Z.M.; Li C.B.; Liu Q.L.; Li P.; Yang H.; Ginsenoside Rg1 prevents doxorubicin-induced cardiotoxicity through the inhibition of autophagy and endoplasmic reticulum stress in Mice. Int J Mol Sci 2018,19(11),E3658","journal-title":"Int J Mol Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"506214","DOI":"10.1155\/2012\/506214","volume":"2012","author":"Wang H.","year":"2012","unstructured":"Wang H.; Yu P.; Gou H.; Zhang J.; Zhu M.; Wang Z.H.; Tian J.W.; Jiang Y.T.; Fu F.H.; Cardioprotective effects of 20(S)-ginsenoside Rh2 against Doxorubicin-Induced cardiotoxicity in vitro and in in vivo. Evid Based Complement Alternat Med 2012,2012,506214","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/cvr\/cvn346","volume":"82","author":"Jenkins C.M.","year":"2009","unstructured":"Jenkins C.M.; Cedars A.; Gross R.W.; Eicosanoid signalling pathways in the heart. Cardiovasc Res 2009,82(2),240-249","journal-title":"Cardiovasc Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1172\/JCI5897","volume":"103","author":"Cyrus T.","year":"1999","unstructured":"Cyrus T.; Witztum J.L.; Rader D.J.; Tangirala R.; Fazio S.; Linton M.F.; Funk C.D.; Disruption of the 12\/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999,103(11),1597-1604","journal-title":"J Clin Invest"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00204-014-1419-z","volume":"90","author":"Maayah Z.H.","year":"2016","unstructured":"Maayah Z.H.; El-Kadi A.O.; 5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-\u03baB-dependent mechanism. Arch Toxicol 2016,90(2),359-373","journal-title":"Arch Toxicol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00204-015-1620-8","volume":"90","author":"Maayah Z.H.","year":"2016","unstructured":"Maayah Z.H.; El-Kadi A.O.; The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy. Arch Toxicol 2016,90(1),119-136","journal-title":"Arch Toxicol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10565-015-9308-7","volume":"31","author":"Maayah Z.H.","year":"2015","unstructured":"Maayah Z.H.; Abdelhamid G.; El-Kadi A.O.; Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-\u03baB. Cell Biol Toxicol 2015,31(4-5),241-259","journal-title":"Cell Biol Toxicol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.phrs.2015.12.016","volume":"105","author":"Maayah Z.H.","year":"2016","unstructured":"Maayah Z.H.; Althurwi H.N.; Abdelhamid G.; Lesyk G.; Jurasz P.; El-Kadi A.O.; CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism. Pharmacol Res 2016,105,28-43","journal-title":"Pharmacol Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1111\/bph.12066","volume":"168","author":"Althurwi H.N.","year":"2013","unstructured":"Althurwi H.N.; Tse M.M.; Abdelhamid G.; Zordoky B.N.; Hammock B.D.; El-Kadi A.O.; Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy. Br J Pharmacol 2013,168(8),1794-1807","journal-title":"Br J Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41021-017-0076-x","volume":"39","author":"Shiizaki K.","year":"2017","unstructured":"Shiizaki K.; Kawanishi M.; Yagi T.; Modulation of benzo[a]pyrene-DNA adduct formation by CYP1 inducer and inhibitor. Genes Environ 2017,39(1),14","journal-title":"Genes Environ"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.10.013","volume":"63","author":"D\u2019Uva G.","year":"2018","unstructured":"D\u2019Uva G.; Baci D.; Albini A.; Noonan D.M.; Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment. Cancer Treat Rev 2018,63,1-18","journal-title":"Cancer Treat Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1124\/mol.113.087700","volume":"84","author":"Nishida C.R.","year":"2013","unstructured":"Nishida C.R.; Everett S.; Ortiz de Montellano P.R.; Specificity determinants of CYP1B1 estradiol hydroxylation. Mol Pharmacol 2013,84(3),451-458","journal-title":"Mol Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1021\/tx700191p","volume":"21","author":"Bolton J.L.","year":"2008","unstructured":"Bolton J.L.; Thatcher G.R.; Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008,21(1),93-101","journal-title":"Chem Res Toxicol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood-2008-03-145219","volume":"113","author":"Tang Y.","year":"2009","unstructured":"Tang Y.; Scheef E.A.; Wang S.; Sorenson C.M.; Marcus C.B.; Jefcoate C.R.; Sheibani N.; CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression. Blood 2009,113(3),744-754","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"113733","DOI":"10.1016\/j.bcp.2019.113733","volume":"171","author":"Lin H.","year":"2020","unstructured":"Lin H.; Hu B.; He X.; Mao J.; Wang Y.; Wang J.; Zhang T.; Zheng J.; Peng Y.; Zhang F.; Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT\/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Biochem Pharmacol 2020,171,113733","journal-title":"Biochem Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3892\/ijmm.2014.2041","volume":"35","author":"Zhu Z.","year":"2015","unstructured":"Zhu Z.; Mu Y.; Qi C.; Wang J.; Xi G.; Guo J.; Mi R.; Zhao F.; CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in in vivo and in vitro. Int J Mol Med 2015,35(2),340-348","journal-title":"Int J Mol Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1021\/acs.jmedchem.5b00265","volume":"58","author":"Cui J.","year":"2015","unstructured":"Cui J.; Meng Q.; Zhang X.; Cui Q.; Zhou W.; Li S.; Design and synthesis of new \u03b1-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression. J Med Chem 2015,58(8),3534-3547","journal-title":"J Med Chem"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejps.2019.02.016","volume":"131","author":"Sonawane V.R.","year":"2019","unstructured":"Sonawane V.R.; Siddique M.U.M.; Gatchie L.; Williams I.S.; Bharate S.B.; Jayaprakash V.; Sinha B.N.; Chaudhuri B.; CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1\/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1\/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance. Eur J Pharm Sci 2019,131,177-194","journal-title":"Eur J Pharm Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"105295","DOI":"10.1016\/j.bioorg.2021.105295","volume":"116","author":"Chen P.","year":"2021","unstructured":"Chen P.; Wang S.; Cao C.; Ye W.; Wang M.; Zhou C.; Chen W.; Zhang X.; Zhang K.; Zhou W.; \u03b1-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship. Bioorg Chem 2021,116,105295","journal-title":"Bioorg Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6310","DOI":"10.1016\/j.bmc.2010.07.020","volume":"18","author":"Takemura H.","year":"2010","unstructured":"Takemura H.; Itoh T.; Yamamoto K.; Sakakibara H.; Shimoi K.; Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem 2010,18(17),6310-6315","journal-title":"Bioorg Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1016\/j.bmc.2011.03.042","volume":"19","author":"Androutsopoulos V.P.","year":"2011","unstructured":"Androutsopoulos V.P.; Papakyriakou A.; Vourloumis D.; Spandidos D.A.; Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg Med Chem 2011,19(9),2842-2849","journal-title":"Bioorg Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"112028","DOI":"10.1016\/j.ejmech.2019.112028","volume":"189","author":"Zhou L.","year":"2020","unstructured":"Zhou L.; Chen W.; Cao C.; Shi Y.; Ye W.; Hu J.; Wang L.; Zhou W.; Design and synthesis of \u03b1-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Eur J Med Chem 2020,189,112028","journal-title":"Eur J Med Chem"},{"key":"ref=39","author":"Zhao T.","year":"2021","unstructured":"Zhao T.; Chen Y.; Wang D.; Wang L.; Dong P.; Zhao S.; Wang C.; Meng Q.; Sun H.; Liu K.; Wu J.; Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant. Cardiovasc Drugs Ther 2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1021\/ac000650l","volume":"72","author":"Li W.","year":"2000","unstructured":"Li W.; Gu C.; Zhang H.; Awang D.V.; Fitzloff J.F.; Fong H.H.; van Breemen R.B.; Use of high-performance liquid chromatography-tandem mass spectrometry to distinguish Panax ginseng C. A. Meyer (Asian ginseng) and Panax quinquefolius L. (North American ginseng). Anal Chem 2000,72(21),5417-5422","journal-title":"Anal Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/13880209.2020.1742167","volume":"58","author":"Yang L.","year":"2020","unstructured":"Yang L.; Zhang C.; Chen J.; Zhang S.; Pan G.; Xin Y.; Lin L.; You Z.; Shenmai injection suppresses multidrug resistance in MCF-7\/ADR cells through the MAPK\/NF-\u03baB signalling pathway. Pharm Biol 2020,58(1),276-285","journal-title":"Pharm Biol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1002\/jcb.27732","volume":"120","author":"Gu B.","year":"2019","unstructured":"Gu B.; Wang J.; Song Y.; Wang Q.; Wu Q.; The inhibitory effects of ginsenoside Rd on the human glioma U251 cells and its underlying mechanisms. J Cell Biochem 2019,120(3),4444-4450","journal-title":"J Cell Biochem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1142\/S0192415X17500240","volume":"45","author":"Jin L.","year":"2017","unstructured":"Jin L.; Xu M.; Luo X.H.; Zhu X.F.; Stephania tetrandra and ginseng-containing Chinese herbal formulation nsenl reverses cisplatin resistance in lung cancer xenografts. Am J Chin Med 2017,45(2),385-401","journal-title":"Am J Chin Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"PL209","DOI":"10.1016\/S0024-3205(99)00407-5","volume":"65","author":"Henderson G.L.","year":"1999","unstructured":"Henderson G.L.; Harkey M.R.; Gershwin M.E.; Hackman R.M.; Stern J.S.; Stresser D.M.; Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999,65(15),PL209-PL214","journal-title":"Life Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/00045391-200405000-00009","volume":"11","author":"He N.","year":"2004","unstructured":"He N.; Edeki T.; The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004,11(3),206-212","journal-title":"Am J Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/toxsci\/kfj164","volume":"91","author":"Liu Y.","year":"2006","unstructured":"Liu Y.; Zhang J.W.; Li W.; Ma H.; Sun J.; Deng M.C.; Yang L.; Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 2006,91(2),356-364","journal-title":"Toxicol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ejmech.2017.02.032","volume":"130","author":"Mohd Siddique M.U.","year":"2017","unstructured":"Mohd Siddique M.U.; McCann G.J.; Sonawane V.R.; Horley N.; Gatchie L.; Joshi P.; Bharate S.B.; Jayaprakash V.; Sinha B.N.; Chaudhuri B.; Quinazoline derivatives as selective CYP1B1 inhibitors. Eur J Med Chem 2017,130,320-327","journal-title":"Eur J Med Chem"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.biopha.2018.10.081","volume":"109","author":"Zhang N.","year":"2019","unstructured":"Zhang N.; An X.; Lang P.; Wang F.; Xie Y.; Ginsenoside Rd contributes the attenuation of cardiac hypertrophy in in vivo and in vitro. Biomed Pharmacother 2019,109,1016-1023","journal-title":"Biomed Pharmacother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1111\/1750-3841.15505","volume":"85","author":"Xue Y.","year":"2020","unstructured":"Xue Y.; Fu W.; Liu Y.; Yu P.; Sun M.; Li X.; Yu X.; Sui D.; Ginsenoside Rb2 alleviates myocardial ischemia\/reperfusion injury in rats through SIRT1 activation. J Food Sci 2020,85(11),4039-4049","journal-title":"J Food Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e2001007","DOI":"10.1002\/cbdv.202001007","volume":"18","author":"Zhao Y.","year":"2021","unstructured":"Zhao Y.; Wang Y.; Zhang M.; Gao Y.; Yan Z.; Protective effects of ginsenosides (20R)-Rg3 on H2 O2 -induced myocardial cell injury by activating Keap-1\/Nrf2\/HO-1 signaling pathway. Chem Biodivers 2021,18(4),e2001007","journal-title":"Chem Biodivers"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220601102629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205489\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220601102629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:15:58Z","timestamp":1692036958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205489\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200223666220601102629","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}